Work

Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States

Year: 2017

Type: article

Abstract: Reply to: Patel J, Zhao X, Shah D, Alhussain K, Kamal K. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. htt...

Source: Journal of Medical Economics

DOI: 10.1080/13696998.2017.1360313

Authors: Catherine Saint-Laurent Thibault, Divya Moorjaney, Michael L. Ganz, Bruce Sill, Shalini Hede, Yong Yuan, Boris Gorsh

Institutions: Concordia University, Bristol-Myers Squibb (United States), GlaxoSmithKline (United States)

Language: English

Topic: Hepatitis C virus research

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4234643552

FWCI:

Cites: 14

Cited by:

Related to: 10